SRPT Q3 2020 Earnings — Sarepta Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SRPTSarepta Therapeutics, Inc.

$2B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$144M+45.3% YoY

Gross Profit

$129M89.6% margin

Operating Income

-$137M-95.2% margin

Net Income

-$196M-136.5% margin

EPS (Diluted)

$-2.50

QoQ Revenue Growth

+4.8%

Cash Flow

Operating Cash Flow

-$238M

Free Cash Flow

-$263M

Stock-Based Comp.

$27M

Balance Sheet

Total Assets

$2.8B

Total Liabilities

$1.9B

Stockholders' Equity

$892M

Cash & Equivalents

$1.5B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$144M	$99M	+45.3%
Gross Profit	$129M	$86M	+49.9%
Operating Income	-$137M	-$124M	-10.9%
Net Income	-$196M	-$126M	-55.5%